44 results on '"De Cesaris, Francesco"'
Search Results
2. Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ)
- Author
-
Onofri, Agnese, Iannone, Luigi Francesco, Granato, Antonio, Garascia, Gabriele, Bartole, Luca, Manganotti, Paolo, Vollono, Catello, Romozzi, Marina, Sottani, Costanza, Calabresi, Paolo, Tassorelli, Cristina, Sances, Grazia, Allena, Marta, De Icco, Roberto, De Cesaris, Francesco, Burgalassi, Andrea, Chiarugi, Alberto, Baraldi, Carlo, Guerzoni, Simona, Prudenzano, Maria Pia, Fallacara, Adriana, Albanese, Maria, Rainero, Innocenzo, Coppola, Gianluca, Casalena, Alfonsina, Mampreso, Edoardo, Pistoia, Francesca, Sarchielli, Paola, Morson, Marisa, Sacco, Simona, Geppetti, Pierangelo, and Ornello, Raffaele
- Published
- 2023
- Full Text
- View/download PDF
3. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine
- Author
-
Iannone, Luigi Francesco, Fattori, Davide, Marangoni, Martina, Benemei, Silvia, Chiarugi, Alberto, Geppetti, Pierangelo, and De Cesaris, Francesco
- Published
- 2023
- Full Text
- View/download PDF
4. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
- Author
-
Iannone, Luigi Francesco, Fattori, Davide, Benemei, Silvia, Chiarugi, Alberto, Geppetti, Pierangelo, and De Cesaris, Francesco
- Published
- 2022
- Full Text
- View/download PDF
5. Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series
- Author
-
Iannone, Luigi Francesco, Fattori, Davide, Geppetti, Pierangelo, and De Cesaris, Francesco
- Published
- 2022
- Full Text
- View/download PDF
6. COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report
- Author
-
Iannone, Luigi Francesco, Geppetti, Pierangelo, Chiarugi, Alberto, and De Cesaris, Francesco
- Published
- 2021
- Full Text
- View/download PDF
7. Low-dose methadone for refractory chronic migraine accompanied by medication-overuse headache: a prospective cohort study
- Author
-
Benemei, Silvia, Lupi, Chiara, De Cesaris, Francesco, Lombardi, Niccolò, Bettiol, Alessandra, Chiarugi, Alberto, Geppetti, Pierangelo, Galli, Valentina, Pracucci, Chiara, Occupati, Brunella, and Mannaioni, Guido
- Published
- 2021
- Full Text
- View/download PDF
8. Long-Term Treatment with the Calcitonin Gene-Related Peptide Receptor Antagonist Erenumab in CADASIL: Two Case Reports.
- Author
-
Albanese, Maria, Pescini, Francesca, Di Bonaventura, Chiara, Iannone, Luigi Francesco, Bianchi, Silvia, Poggesi, Anna, Bengala, Mario, Mercuri, Nicola Biagio, and De Cesaris, Francesco
- Subjects
CALCITONIN gene-related peptide ,MIGRAINE aura ,ERENUMAB ,CEREBRAL small vessel diseases ,PEPTIDE receptors ,CEREBRAL ischemia - Abstract
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common monogenic form of cerebral small vessel disease, caused by a mutation in the NOTCH3 gene on chromosome 19. The main clinical features include migraine (often with aura), early onset, recurrent subcortical ischemic strokes, mood disturbances, and cognitive impairment, frequently leading to dementia and disability with a reduction in life expectancy. Cerebral chronic global hypoperfusion, due to impaired cerebrovascular reactivity, seems to play a primary role in CADASIL. Migraine is the most common early feature of the disease, and to date, there are no consensus guidelines for treatment. Given the vasomodulatory influence of many antimigraine drugs, there is concern about their use in this disease. In particular, the calcitonin gene-related peptide (CGRP) system serves as a vasodilatory protective mechanism during cerebral and cardiac ischemia. Blocking this system could exacerbate ischemic events. Herein, we describe two CADASIL patients who were treated with the calcitonin gene-related peptide (CGRP) receptor antagonist erenumab for chronic migraine, reporting a significant reduction in the frequency of attacks and intensity of pain, and an improvement in quality of life without adverse effects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Changes in grey matter volume and functional connectivity in cluster headache versus migraine
- Author
-
Giorgio, Antonio, Lupi, Chiara, Zhang, Jian, De Cesaris, Francesco, Alessandri, Mario, Mortilla, Marzia, Federico, Antonio, Geppetti, Pierangelo, De Stefano, Nicola, and Benemei, Silvia
- Published
- 2020
- Full Text
- View/download PDF
10. Patterns of anti‐CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
- Author
-
Hyeraci, Giulia, Paoletti, Olga, Iannone, Luigi Francesco, Gini, Rosa, De Cesaris, Francesco, Geppetti, Pierangelo, and Roberto, Giuseppe
- Subjects
MIGRAINE prevention ,THERAPEUTIC use of monoclonal antibodies ,DRUG tolerance ,NEUROPEPTIDES ,RESEARCH methodology ,CALCITONIN ,RETROSPECTIVE studies ,MEDICAL care costs ,TREATMENT effectiveness ,COMPARATIVE studies ,DRUG prescribing ,KAPLAN-Meier estimator ,DESCRIPTIVE statistics ,COST effectiveness ,RESEARCH funding ,DRUG utilization ,PHYSICIAN practice patterns ,LONGITUDINAL method ,PATIENT safety ,CHEMICAL inhibitors - Abstract
Objective: To describe the pattern of anti‐calcitonin gene–related peptide monoclonal antibodies (anti‐CGRP mAbs) utilization in the Tuscany region, Italy, and the variation of triptan consumption after treatment initiation. Background: Given the recent commercialization of anti‐CGRP mAbs as migraine preventive medications, real‐world evidence on their patterns of utilization and their impact on migraine abortive medication use is still limited. Methods: A retrospective, descriptive, cohort study on the real‐world utilization of anti‐CGRP mAbs was performed using the population‐based regional administrative database of Tuscany. Patients with ≥1 anti‐CGRP mAb dispensing (namely erenumab, galcanezumab, fremanezumab) between April 1, 2019, and September 30, 2021, were identified. The first dispensing was the cohort entry (CE). New users (NUs) were patients with no anti‐CGRP mAb dispensing before CE. Kaplan–Meier (KM) curves were plotted to describe the cumulative probability of remaining with the initial anti‐CGRP mAb during a 15‐month follow‐up period as a measure of treatment persistence. Among NUs with ≥2 triptan dispensings during the 6 months before CE (i.e., baseline), the mean monthly number of triptan dosage units dispensed was measured in five consecutive follow‐up time windows (months 1–3, 4–6, 7–9, 10–12, 13–15) and the difference from the baseline was calculated. Results: A total of 624 NUs (erenumab = 295, galcanezumab = 223, fremanezumab = 106) were identified, of whom 188 (78%) were women. Mean age was 49.2 years (standard deviation [SD] = 12.6). The survival to discontinuation at 6, 12, and 15 months was about 69%, 48%, and 6%, respectively. The survival to switch was about 6% at 15 months. The observed variation of triptan consumption at 3/6/9/12/15 months and the corresponding SD was −4.4 [8.2]/−5.2 [9.0]/−5.5 [9.2]/−5.4 [9.2]/−4.5 [10.0], respectively. Conclusion: Patient demographics reflect the place of these medications in therapy. Overall, findings seem to indicate a favorable tolerability and effectiveness profile. Further studies are warranted to better establish the long‐term comparative effectiveness, safety, and cost effectiveness of anti‐CGRP mAbs compared to other preventive medications. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Migraine-provoking substances evoke periorbital allodynia in mice
- Author
-
De Logu, Francesco, Landini, Lorenzo, Janal, Malvin N., Li Puma, Simone, De Cesaris, Francesco, Geppetti, Pierangelo, and Nassini, Romina
- Published
- 2019
- Full Text
- View/download PDF
12. Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine
- Author
-
Sacco, Simona, Benemei, Silvia, Cevoli, Sabina, Coppola, Gianluca, Cortelli, Pietro, De Cesaris, Francesco, De Icco, Roberto, De Marco, Cristiano Maria, Di Lorenzo, Cherubino, Geppetti, Pierangelo, Manni, Alessia, Negro, Andrea, Ornello, Raffaele, Pierangeli, Giulia, Pierelli, Francesco, Pellesi, Lanfranco, Pini, Luigi Alberto, Pistoia, Francesca, Prudenzano, Maria Pia, Russo, Antonio, Sances, Grazia, Taranta, Valentina, Tassorelli, Cristina, Tedeschi, Gioacchino, Trojano, Maria, and Martelletti, Paolo
- Published
- 2019
- Full Text
- View/download PDF
13. Protocol and methods for testing the efficacy of well-being therapy in chronic migraine patients: a randomized controlled trial
- Author
-
Mansueto, Giovanni, De Cesaris, Francesco, Geppetti, Pierangelo, and Cosci, Fiammetta
- Published
- 2018
- Full Text
- View/download PDF
14. Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany.
- Author
-
Hyeraci, Giulia, Gini, Rosa, Bezin, Julien, Iannone, Luigi Francesco, Benemei, Silvia, Lupi, Chiara, De Cesaris, Francesco, Geppetti, Pierangelo, and Roberto, Giuseppe
- Subjects
CARDIOVASCULAR diseases risk factors ,TRYPTAMINE ,MIGRAINE ,AGE distribution ,SEROTONIN ,RETROSPECTIVE studies ,MEDICAL care use ,SEX distribution ,DRUGS ,DESCRIPTIVE statistics ,PATIENT safety ,LONGITUDINAL method ,COMORBIDITY - Abstract
Objective: To describe the pattern of triptan use by gender in Tuscany, Italy, focusing on special user populations in which evidence on triptan safety is still not conclusive. Background: Growing evidence supports the role of gender differences in migraine pathophysiology and treatment. However, gender impact on triptan real‐word utilization has been poorly investigated. Methods: A retrospective, descriptive, cohort study was performed using the population‐based Administrative Healthcare Database of Tuscany region (Italy). Subjects registered in the database on the January 1 of each year between 2008 and 2018 were identified. New users (NU) of triptans (ATC:N02CC*) were patients with one or more triptan dispensation during the year of interest and none in the past. Age, cardiovascular comorbidities representing an absolute or a possible contraindication to triptan utilization, concomitant serotonergic medications, and pattern of triptan use during 1‐year follow‐up were described by gender. Results: A total of 86,109 patients who received one or more triptan dispensing were identified. Of 64,672 NU (men = 17,039; women = 47,633), 10.2% (6823/64,672) were aged >65 years, who were mostly women (n = 4613). Among NU, men and women with absolute cardiovascular contraindications were 4.3% (740/17,039) and 2.1% (1022/47,633), respectively, while those concomitantly taking serotonergic medications were 17.2% (267/1549) and 21.9% (949/4330), respectively (949/4330). Regular users (two or more dispensing with ≥3 months between first and last observed dispensing) accounted for 26.4% of women (12,597/47,633) and 19.11% of men (3250/17,039); frequent users (≥15 dosage units/month during ≥3 consecutive months) were overall 0.1% (94/64,672) and 62.0% (58/94) of them concomitantly received serotonergic medications. Conclusion: Considering gender differences in triptan use highlighted here, large scale observational studies are warranted to better define what populations are safe to use triptans and whether it is appropriate to tighten or relax certain recommendations on triptan use. In the meantime, any suspected adverse drug reaction observed in the special user populations highlighted in this study should be promptly reported. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
- Author
-
Iannone, Luigi Francesco, De Cesaris, Francesco, Ferrari, Anita, Benemei, Silvia, Fattori, Davide, and Chiarugi, Alberto
- Subjects
- *
MONOCLONAL antibodies , *MIGRAINE aura , *MIGRAINE , *ERENUMAB , *PEPTIDES , *PANIC attacks - Abstract
Background: Clinical trials and observational studies with anti-calcitonin gene-related peptide antibodies poorly investigated their impact on migraine prodromal and accompanying symptoms. This information might help deciphering the biologics' pharmacodynamic and provide hints on migraine pathogenesis. Herein, we report the effects of erenumab, fremanezumab and galcanezumab on attack prodromal and accompanying symptoms and on neurological and psychiatric traits. Methods: An explorative, prospective, questionnaire-based study was completed by a cohort (n = 80) of patients with chronic migraine patients presenting a sustained reduction of ≥50% of Migraine Disability Assessment Score and ≥30% of monthly migraine days three months after anti-calcitonin gene-related peptide antibodies treatment. Results: The majority of patients experienced a complete prevention of migraine symptoms without evidence of initial onset followed by attack abortion. Few patients reported the recurrence of prodromal (from 10% to 12.5%) or accompanying (from 1.3% to 8.8%) symptoms without headache. All patients with migraine with aura reported a decrease of aura incidence. Sleep changes (51.2%), increase in appetite (20.0%) and weight (18.8%) as well as a reduction in stress (45.0%), anxiety (26.3%), and panic attacks (15%) were also reported. Conclusion: Anti-calcitonin gene-related peptide antibodies seems to significantly impact brain functions of migraineurs, preventing not only migraine headache but also its anticipatory and accompanying symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study.
- Author
-
Geppetti, Pierangelo, De Cesaris, Francesco, Benemei, Silvia, Cortelli, Pietro, Cevoli, Sabina, Pierangeli, Giulia, Favoni, Valentina, Lisotto, Carlo, Usai, Susanna, Frediani, Fabio, Di Fiore, Paola, D'Arrigo, Giacomo, Tassorelli, Cristina, Sances, Grazia, Cainazzo, Maria Michela, Baraldi, Carlo, Sarchielli, Paola, Corbelli, Ilenia, De Vanna, Gioacchino, and Tedeschi, Gioacchino
- Subjects
- *
DICLOFENAC , *MIGRAINE , *SUBCUTANEOUS injections , *PILOT projects , *ORAL drug administration - Abstract
Background: A novel formulation of diclofenac, complexed with hydroxypropyl-β-cyclodextrin (HPβCD) as a solubility enhancer, in a prefilled syringe for self-administered subcutaneous injection may overcome the limitations of acute migraine treatments administered by oral, rectal, intramuscular, or intravenous routes. Methods: This multicentre, phase 2, double-blind, randomized, placebo-controlled, dose-finding pilot study evaluated the efficacy, safety and tolerability of three different doses (25/50/75 mg/1 mL) of subcutaneous diclofenac sodium in the treatment of an acute migraine attack in 122 subjects. The primary efficacy endpoint was the percentage of patients pain-free at 2 hours after the study drug injection. Results: A significantly higher percentage of patients in the 50 mg diclofenac group 14 (46.7%) were pain-free at 2 hours when compared with placebo: 9 (29.0%) (p = 0.01). The 50 mg dose proved superior to placebo also in the majority of the secondary endpoints. The overall global impression favoured diclofenac vs placebo. There were no adverse events leading to study withdrawal. The majority of treatment-emergent adverse events were mild. Conclusions: The 50 mg dose of this novel formulation of diclofenac represents a valuable self-administered option for the acute treatment of migraine attacks. Trial registration: EudraCT Registration No. 2017-004828-29. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. TRPA1 and other TRP channels in migraine
- Author
-
Benemei, Silvia, De Cesaris, Francesco, Fusi, Camilla, Rossi, Eleonora, Lupi, Chiara, and Geppetti, Pierangelo
- Published
- 2013
- Full Text
- View/download PDF
18. Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine.
- Author
-
Iannone, Luigi Francesco, Fattori, Davide, Benemei, Silvia, Chiarugi, Alberto, Geppetti, Pierangelo, and De Cesaris, Francesco
- Subjects
PEPTIDES ,MIGRAINE ,ERENUMAB ,IMPACT testing ,IMMUNOGLOBULINS ,CD20 antigen ,BOTULINUM A toxins - Abstract
Background and purpose: Guidelines for migraine prophylaxis suggest stopping medication after 6–12 months to reevaluate treatment appropriateness. The Italian Medicines Agency set a mandatory regulation to stop anti‐calcitonin gene related protein (CGRP) pathway monoclonal antibody (anti‐CGRP mAb) treatments for 3 months after 12 months of treatment. Herein, the effects of discontinuation and retreatment of anti‐CGRP mAbs in resistant chronic migraine patients are assessed, evaluating predictive factors of sustained response. Methods: This was a monocentric prospective cohort study, enrolling 44 severe (resistant to ≥3 preventive treatments) chronic migraine patients (all with medication‐overuse), treated with erenumab (54.5%) or galcanezumab (45.5%) for 12 months, who discontinued treatment for 3 months and then restarted for 1 month. Results: Overall, patients reported an increasing deteriorating trend during the 3 months of discontinuation. Monthly migraine days, number of analgesics, days with at least one analgesic used, a ≥50% response rate (reduction in monthly migraine days), and Migraine Disability Assessment Score and Headache Impact Test 6 total score, remained lower than baseline values, but increased compared to month 12 of treatment. All outcome measures decreased again during the month of retreatment. Patients who did not meet criteria for restarting treatment had a lower Migraine Disability Assessment Score (p = 0.03) and Headache Impact Test 6 (p = 0.01) score at baseline and better outcome measures during discontinuation compared to patients who restarted treatment. Conclusions: In most patients, the 3‐month discontinuation of anti‐CGRP mAbs resulted in progressive migraine deterioration that was rapidly reverted by retreatment. However, one‐quarter of patients who reported better quality of life indices before treatment showed a sustained benefit during discontinuation and did not need retreatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Chronic headaches and medication overuse
- Author
-
Geppetti, Pierangelo, De Cesaris, Francesco, Nicoletti, Paola, and Benemei, Silvia
- Published
- 2010
- Full Text
- View/download PDF
20. Emerging Pharmacological Treatments for Migraine in the Pediatric Population.
- Author
-
Iannone, Luigi Francesco, De Cesaris, Francesco, and Geppetti, Pierangelo
- Subjects
- *
PEDIATRIC therapy , *DRUG therapy , *CALCITONIN gene-related peptide , *PRIMARY headache disorders , *PLACEBOS - Abstract
Headaches in children and adolescents have high incidence and prevalence rates, with consequent elevated disability costs to individuals and the community. Pediatric migraine is a disorder with substantial clinical differences compared to the adult form. Few clinical trials have been performed specifically on primary headache in pediatric populations using acute and preventative treatments, often with conflicting findings. The limited high-quality data on the effectiveness of treatments are also due to the high placebo effect, in terms of reductions in both the frequency and intensity of migraine attacks in the pediatric population. The recent introduction of calcitonin gene-related peptide (CGRP) pathway inhibitors and ditans is changing the treatment of migraine, but the majority of the data are still limited to adulthood. Thus, few drugs have indications for migraine treatment in the pediatric age group, and limited evidence gives guidance as to the choice of pharmacotherapy. Herein, we review the current evidence of pharmacological treatments and ongoing clinical trials on acute and preventative treatments in the pediatric population with migraine. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. O062. Post ambulatory surgery headache in patients affected from primary headaches: a comparison with the general population
- Author
-
Manfredi, Giovanni F, De Cesaris, Francesco, and Tomas Roldan, Eugenia
- Published
- 2015
- Full Text
- View/download PDF
22. P010. OnabotulinumtoxinA for treatment of chronic migraine: results after 1 year of treatment
- Author
-
Rossi, Eleonora, Lupi, Chiara, Benemei, Silvia, Geppetti, Pierangelo, and De Cesaris, Francesco
- Published
- 2015
- Full Text
- View/download PDF
23. P057. Prophylaxis with low-dose methadone in patients affected by daily refractory headache and medication-overuse headache: a prospective cohort study (METACEF study)
- Author
-
Lupi, Chiara, Pracucci, Chiara, De Cesaris, Francesco, Rossi, Eleonora, Geppetti, Pierangelo, Benemei, Silvia, Galli, Valentina, Occupati, Brunella, Mazzucco, Viola, and Mannaioni, Guido
- Published
- 2015
- Full Text
- View/download PDF
24. CGRP receptors and TRP channels in migraine
- Author
-
Geppetti, Pierangelo, Benemei, Silvia, and De Cesaris, Francesco
- Published
- 2015
- Full Text
- View/download PDF
25. Arterial hypertension and migraine: comorbidity or something else?
- Author
-
Fanciullacci, Marcello, Alessandri, Massimo, De Cesaris, Francesco, and Pietrini, Umberto
- Published
- 2004
- Full Text
- View/download PDF
26. Preventing chronicity of migraine
- Author
-
Fanciullacci, Marcello and De Cesaris, Francesco
- Subjects
Migraine -- Physiological aspects ,Migraine -- Drug therapy ,Migraine -- Development and progression ,Chronic pain -- Drug therapy ,Chronic pain -- Prevention ,Health - Published
- 2005
27. Investigating the Effects of COVID-19 Quarantine in Migraine: An Observational Cross-Sectional Study From the Italian National Headache Registry (RICe).
- Author
-
Delussi, Marianna, Gentile, Eleonora, Coppola, Gianluca, Prudenzano, Addolorata Maria Pia, Rainero, Innocenzo, Sances, Grazia, Abagnale, Chiara, Caponnetto, Valeria, De Cesaris, Francesco, Frattale, Ilaria, Guaschino, Elena, Marcinnò, Andrea, Ornello, Raffaele, Pistoia, Francesca, Putortì, Alessia, Roca, Maria Elena, Roveta, Fausto, Lupi, Chiara, Trojano, Maria, and Pierelli, Francesco
- Subjects
COVID-19 ,COVID-19 pandemic ,MIGRAINE aura ,HEADACHE ,MIGRAINE ,QUARANTINE ,PRIMARY headache disorders ,POST-traumatic stress - Abstract
Background: Previous studies during SARS and Ebola pandemics have shown that quarantine is associated with several negative psychological effects, such as post-traumatic stress symptoms, confusion, and anger. These conditions may affect the course of many diseases, including migraine. Although it is possible that the quarantine measures for the current COVID-19 pandemic affect migraine burden, no information is currently available on this issue. Aim: In this study, we aimed to: (1) explore the possible changes in migraine frequency, severity, and days with acute medication intake during quarantine period; (2) evaluate possible differences in migraine outcomes in consideration of lifestyle changes, emotions, pandemic diffusion, and COVID-19 infection. Methods: We interviewed patients who were included in the observational Italian Headache Registry (Registro Italiano Cefalee, RICE), retrospectively collecting information on main headache features, lifestyle factors, emotions, individual infection status, and perception of COVID-19 for 2 months before (pre-quarantine) and after the beginning of the quarantine (quarantine). Inclusion criteria were: age > 18, diagnosis of migraine without aura, migraine with aura and chronic migraine, last in-person visit more than 3 months preceding the beginning of quarantine. Results: A total of 433 migraine subjects agreed to be interviewed. We found an overall reduction in headache frequency (9.42 ± 0.43 days with headache vs. 8.28 ± 0.41) and intensity (6.57 ± 0.19 vs. 6.59 ± 0.21) during the quarantine, compared to pre-quarantine. There was a correlation between improvement and number of days of stay-at-home. When results were stratified for geographic area, we found a tendency toward worsening of headache frequency in northern Italy. Disgust regarding viral infection corresponded to a minor improvement in migraine. Conclusions: Migraine patients showed a mild improvement of migraine features, probably attributable to resilient behavior toward pandemic distress. Disgust regarding the contagion whereas potentially favoring defensive behavior, could potentially worsen migraine. The spontaneous limitation of migraine burden during quarantine could favor patient follow-up via the use of telemedicine visits, reliable diaries, and frequent remote contacts. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Defining neuralgiform headache with ipsilateral autonomic symptoms: case report in a headache center
- Author
-
De Cesaris, Francesco, Fanciullacci, Marcello, Pietrini, Umberto, Anselmi, Bruno, and Del Bene, Enrico
- Published
- 2008
- Full Text
- View/download PDF
29. Migraine during COVID-19: Data from Second Wave Pandemic in an Italian Cohort.
- Author
-
Gentile, Eleonora, Delussi, Marianna, Abagnale, Chiara, Caponnetto, Valeria, De Cesaris, Francesco, Frattale, Ilaria, Guaschino, Elena, Marcinnò, Andrea, Ornello, Raffaele, Pistoia, Francesca, Putortì, Alessia, Candida, Giusy, Roveta, Fausto, Lupi, Chiara, Coppola, Gianluca, Prudenzano, Addolorata Maria Pia, Rainero, Innocenzo, Sances, Grazia, Roca, Maria Elena, and Trojano, Maria
- Subjects
COVID-19 ,COVID-19 pandemic ,PANDEMICS ,MIGRAINE ,MIGRAINE aura ,TREATMENT effectiveness ,PRIMARY headache disorders - Abstract
Objectives: The study aims to assess the impact of the second COVID-19 pandemic wave on migraine characteristics. Methods: This is an observational cross-sectional study conducted on migraine patients previously interviewed during the first Italian pandemic outbreak. A second structured telephone interview was conducted between 20 November 2020 and 18 January 2021. We compared migraine characteristics among T0 (before pandemic), T1 (during the first pandemic phase), and T2 (during the second pandemic phase). Results: Among the 433 patients interviewed during the first pandemic phase, 304 cases were finally considered. One hundred forty-eight patients had a control visit between March 2020 and December 2020, 120 had an in-person visit, 14 by phone, the remainder used telemedicine software provided by the hospital. Frequency of headache, number of symptomatic drugs and headache intensity worsened during T2, compared to T0 and T1, especially in episodic migraine. Headache intensity increased relating to the negative emotional impact of the pandemic. Migraine management during the pandemic did not influence the clinical outcome. Conclusion: The prolongation of the pandemic seems to have a negative impact on migraine evolution. The arousal and negative psychological behavior toward the COVID-19 outbreak seem to worsen migraine. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
- Author
-
Iannone, Luigi Francesco, Burgalassi, Andrea, Vigani, Giulia, Tabasso, Giorgio, De Cesaris, Francesco, Chiarugi, Alberto, and Geppetti, Pierangelo
- Subjects
- *
MONOCLONAL antibodies , *CALCITONIN gene-related peptide , *PEPTIDES , *MEDICATION abuse , *COHORT analysis - Abstract
Background: A pharmacological class effect was initially proposed for monoclonal antibodies against the calcitonin gene related peptide pathway. However, preliminary evidence shows that switching patients who were non-responding to one monoclonal antibody to another could provide some benefit. Herein, we assess treatment response to an anticalcitonin gene related peptide/receptor monoclonal antibody in patients who have failed to respond to anti-calcitonin gene related peptide/ligand monoclonal antibodies calcitonin gene related peptide/ligand monoclonal antibodies and vice versa. In addition, we select non-responders to the first anti-monoclonal antibody by three or five more stringent variables. Methods: Retrospective cohort study including outpatients treated consecutively with two anti-calcitonin gene related peptide monoclonal antibodies. Ineffectiveness to the first monoclonal antibody was assessed using three (MIDAS score, monthly headache days, and analgesic monthly days) variables or five (monthly headache days, MIDAS score, analgesic monthly days, analgesic monthly number and HIT-6 score) variables in the same cohort of patients. The primary endpoints were the absolute change from baseline in monthly headache days, response rate, and persistence in medication overuse at three months of treatment with the second anti-CGRP mAb. Results: In patients selected by three variables, a sustained reduction in monthly headache days, analgesic monthly days, MIDAS and HIT-6 scores was observed at month-3 of treatment with the second monoclonal antibody. Ten (45.4%) patients achieved at least a -30% response rate. No difference was reported switching anti-CGRP mAb against ligand or receptor. In the patient subgroup selected by five variables, only HIT-6 was reduced from baseline at month-3. However, a trend toward a reduction in monthly headache days, analgesic monthly days, and MIDAS score was observed at month-3. Conclusions: Switching anti-calcitonin gene related peptide monoclonal antibodies in selected patients might be an option to achieve or improve clinical benefit. More studies are required to establish the effectiveness of switching these treatments. Conclusions: Switching anti-calcitonin gene related peptide monoclonal antibodies in selected patients might be an option to achieve or improve clinical benefit. More studies are required to establish the effectiveness of switching these treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Acute and chronic triptan exposure neither alters rodent cerebral blood flow nor worsens ischemic brain injury.
- Author
-
Muzzi, Mirko, Buonvicino, Daniela, De Cesaris, Francesco, and Chiarugi, Alberto
- Subjects
- *
PRAZOSIN , *BRAIN injuries , *CEREBRAL circulation , *CARDIOVASCULAR diseases risk factors , *VASOCONSTRICTORS , *DIHYDROERGOTAMINE , *THERAPEUTICS ,CEREBRAL ischemia treatment - Abstract
Although it is still debated whether vasoconstriction underlies migraine resolution by triptans, they are not recommended in patients at cardiovascular risk. However, relationship between stroke incidence and triptan use is unclear, and it is unknown whether acute or chronic use of these drugs worsens ischemic brain injury. To address this issue, we investigated the effect of clinically-relevant doses of the potent cerebral artery vasoconstrictor eletriptan on cerebral blood flow (CBF) and brain infarct volumes, as well as on expression of genes involved in cerebrovascular regulation. We report that acute treatment of rats or mice with eletriptan did not reduce basal CBF, which promptly dropped upon treatment with prazosin or dihydroergotamine. Acute of chronic (1 month) eletriptan also did not affect CBF changes and infarct volumes in mice undergoing brain ischemia/reperfusion. Finally, chronic eletriptan reduced brain mRNAs for PACAP and VIP, leaving unaffected those for 5HT1 B/D R and CGRP. No significant transcript changes were found in dura mater. Data suggest that the impact of triptans on cerebral hemodynamic should be re-evaluated, as well as their propensity to increase stroke risk in migraineurs. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Epidemiology and determinants of chronic migraine: A real-world cohort study, with nested case-control analysis, in primary care in Italy.
- Author
-
Marconi, Ettore, Pecchioli, Serena, Nica, Mihaela, Colombo, Delia, Mazzoleni, Francesco, De Cesaris, Francesco, Geppetti, Pierangelo, Cricelli, Claudio, and Lapi, Francesco
- Subjects
- *
MIGRAINE , *PRIMARY care , *EPIDEMIOLOGY , *COHORT analysis , *GENERAL practitioners , *MIGRAINE aura - Abstract
Background: The proper identification of chronic migraine is one of the mainstays for general practitioners. This study therefore aims to assess the epidemiology and determinants of chronic migraine in primary care in Italy by testing five operational case definition algorithms. Methods: Five case definition algorithms defining chronic migraine were developed to estimate the prevalence and incidence rate of chronic migraine in the Health Search database. For each algorithm, we conducted a nested case-control analysis to quantify the level of association between certain determinants and incident cases of chronic migraine. Results: Considering a cohort of 1,091,032 patients (52% were females), the prevalence rate of chronic migraine increased from the first to the fifth case definition algorithm ranging from 0.03 to 0.28%. No 95% confidence interval overlapped the others, and every confidence interval reliably maintained 2% precision. Incidence rates showed a growing trend (0.008–0.056 per 100,000 person-years) as well. All case definition algorithms were able to capture sex (i.e. female) and nonsteroidal anti-inflammatory drug (NSAID) overuse as statistically significant determinants of incident cases of chronic migraine. Depression was associated with a statistically significant increase of incidence rate of chronic migraine only for two case definition algorithms. Conclusion: Our findings show that prevalence and incidence rate of chronic migraine are underestimated when compared with current literature. On the other hand, we found acceptable correctness of chronic migraine definition in the light of the association with well-known determinants. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: Implication for cluster headache treatment.
- Author
-
Muzzi, Mirko, Zecchi, Riccardo, Ranieri, Giuseppe, Urru, Matteo, Tofani, Lorenzo, De Cesaris, Francesco, Panconesi, Alessandro, and Chiarugi, Alberto
- Subjects
- *
SUMATRIPTAN , *TREATMENT effectiveness , *CLUSTER headache , *PATHOLOGY , *ANALGESIA , *MASS spectrometry - Abstract
Background: In spite of the substantial therapeutic efficacy of triptans, their site of action is still debated. Subcutaneous sumatriptan is the most efficacious symptomatic treatment for cluster headache (CH) patients, showing therapeutic onset within a few minutes after injection even in migraine patients. However, whether subcutaneous sumatriptan is able to reach the CNS within this short time frame is currently unknown.Methods: Here, by means of liquid chromatography/mass spectrometry, we investigated peripheral and brain distribution of subcutaneous sumatriptan soon after injection in rats at a dose equivalent to that used in patients. Tissue sumatriptan contents were compared to those of oxazepam, a prototypical lipophilic, neuroactive drug.Results: We report that sumatriptan accumulated within brain regions of relevance to migraine and CH pathogenesis such as the hypothalamus and the brainstem as soon as 1 and 5 minutes after injection. Notably, sumatriptan brain distribution was faster than that of oxazepam, reaching concentrations exceeding its reported binding affinity for 5HT1B/D receptors, and in the range of those able to inhibit neurotransmitter release in vivo.Conclusion: Our findings indicate that sumatriptan distributes within the CNS soon after injection, and are in line with prompt pain relief by parenteral sumatriptan in CH patients. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
34. Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses.
- Author
-
Felici, Roberta, Buonvicino, Daniela, Muzzi, Mirko, Cavone, Leonardo, Guasti, Daniele, Lapucci, Andrea, Pratesi, Sara, De Cesaris, Francesco, Luceri, Francesca, and Chiarugi, Alberto
- Subjects
- *
RAPAMYCIN , *TREATMENT of neurodegeneration , *PHARMACOLOGY , *PHARMACODYNAMICS , *ULTRASTRUCTURE (Biology) , *SURVIVAL analysis (Biometry) - Abstract
Mitochondrial encephalopathies are fatal, infantile neurodegenerative disorders caused by a deficit of mitochondrial functioning, for which there is urgent need to identify efficacious pharmacological treatments. Recent evidence shows that rapamycin administered both intraperitoneally or in the diet delays disease onset and enhances survival in the Ndufs4 null mouse model of mitochondrial encephalopathy. To delineate the clinical translatability of rapamycin in treatment of mitochondrial encephalopathy, we evaluated the drug's effects on disease evolution and mitochondrial parameters adopting treatment paradigms with fixed daily, oral doses starting at symptom onset in Ndufs4 knockout mice. Molecular mechanisms responsible for the pharmacodynamic effects of rapamycin were also evaluated. We found that rapamycin did not affect disease development at clinically-relevant doses (0.5 mg kg −1 ). Conversely, an oral dose previously adopted for intraperitoneal administration (8 mg kg −1 ) delayed development of neurological symptoms and increased median survival by 25%. Neurological improvement and lifespan were not further increased when the dose raised to 20 mg kg −1 . Notably, rapamycin at 8 mg kg −1 did not affect the reduced expression of respiratory complex subunits, as well as mitochondrial number and mtDNA content. This treatment regimen however significantly ameliorated architecture of mitochondria cristae in motor cortex and cerebellum. However, reduction of mTOR activity by rapamycin was not consistently found within the brain of knockout mice. Overall, data show the ability of rapamycin to improve ultrastructure of dysfunctional mitochondria and corroborate its therapeutic potential in mitochondrial disorders. The non-clinical standard doses required, however, raise concerns about its rapid and safe clinical transferability. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
35. Safety recommendations for treatment with botulinum toxin during the COVID-19 pandemic prepared by the Italian botulinum toxin network in collaboration with the accademia LIMPE-DisMov, SISC, and ANIRCEF associations.
- Author
-
Bono, Francesco, Marchese, Roberta, Albanese, Alberto, De Cesaris, Francesco, Altavista, Maria Concetta, and Eleopra, Roberto
- Subjects
- *
BOTULINUM toxin , *COVID-19 pandemic , *BOTULINUM A toxins , *SURGICAL gloves , *COVID-19 , *MEDICAL personnel , *SAFETY - Published
- 2021
- Full Text
- View/download PDF
36. The role of TRP ion channels in migraine and headache.
- Author
-
Iannone, Luigi Francesco, De Logu, Francesco, Geppetti, Pierangelo, and De Cesaris, Francesco
- Subjects
- *
CANCER pain , *TRP channels , *ION channels , *CALCITONIN gene-related peptide , *MIGRAINE , *SENSORY neurons - Abstract
• The transient receptor potential (TRP) channel family comprise more than 50 members. • Thermo-TRPs were proposed to contribute in transmission/modulation of nociception. • TRPA1 and TRPV4 have been identified also in non-neuronal cells. • TRP stimulation release CGRP, activated or sensitized by endogenous/exogenous stimuli. • TRP channels, and mainly TRPA1, could be involved in migraine pathophysiology. • TRP targeting may be proposed as new targets for therapy. Migraine afflicts more than 10% of the general population. Although its mechanism is poorly understood, recent preclinical and clinical evidence has identified calcitonin gene related peptide (CGRP) as a major mediator of migraine pain. CGRP, which is predominantly expressed in a subset of primary sensory neurons, including trigeminal afferents, when released from peripheral terminals of nociceptors, elicits arteriolar vasodilation and mechanical allodynia, a hallmark of migraine attack. Transient receptor potential (TRP) channels include several cationic channels with pleiotropic functions and ubiquitous distribution in various cells and tissues. Some members of the TRP channel family, such as the ankyrin 1 (TRPA1), vanilloid 1 and 4 (TRPV1 and TRPV4, respectively), and TRPM3, are abundantly expressed in primary sensory neurons and are recognized as sensors of chemical-, heat- and mechanical-induced pain, and play a primary role in several models of pain diseases, including inflammatory, neuropathic cancer pain, and migraine pain. In addition, TRP channel stimulation results in CGRP release, which can be activated or sensitized by various endogenous and exogenous stimuli, some of which have been proven to trigger or worsen migraine attacks. Moreover, some antimigraine medications seem to act through TRPA1 antagonism. Here we review the preclinical and clinical evidence that highlights the role of TRP channels, and mainly TRPA1, in migraine pathophysiology and may be proposed as new targets for its treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. Prophylactic activity of increasing doses of intravenous histamine in refractory migraine: Retrospective observations of a series of patients with migraine without aura
- Author
-
Pietrini, Umberto, De Luca, Massimo, Del Bene, Enrico, De Cesaris, Francesco, Bertinotti, Luca, Colangelo, Nicola, and Moggi Pignone, Alberto
- Subjects
- *
HISTAMINE , *CENTRAL pain , *DRUG dosage , *NEUROPEPTIDES , *HEADACHE treatment , *HOSPITAL care , *MIGRAINE , *PATIENTS - Abstract
Background: Histamine is thought to play a pivotal role in the modulation of peripheral and central pain. The administration of increasing doses of histamine may lead to desensitization of receptors of histamine types 1 and 2, causing meningeal vasodilation, and to depletion of neuropeptides in the trigeminal ganglion, thus inhibiting the initiation of migraine.Objective: In this study, the efficacy and tolerability of increasing doses of IV histamine in migraine prophylaxis were investigated.Methods: This single-center, open-label, retrospective, controlled study was conducted at the Headache Center (Department of Internal Medicine, University of Florence, Villa Monna Tessa, Italy). Patients included in the study had 3 to 6 migraines without aura per month that were refractory to common symptomatic and prophylactic agents in the 6 months preceding the study. Patients were treated with IV histamine hydrochloride for 21 days starting with a dosage of 0.5 mg/d and increasing to 4.0 mg/d. To assess the efficacy of the treatment, these patients were matched for age; sex; and frequency, duration, and severity of attacks with untreated migraineurs. Clinical benefit was defined as ⩽ 1 migraine of mild intensity per month. Tolerability was assessed during the hospitalization period, and patients were instructed to contact the Headache Center to report any adverse effects after hospital discharge.Results: The histamine group comprised 47 patients (40 women, 7 men; mean [SD] age, 42.0 [8.6] years) and the control group comprised 23 patients (20 women, 3 men; mean [SD] age, 38.8 [8.4] years). The histamine-treated patients showed a clinical benefit lasting for a mean of 10.4 (4.2) months, while the patients in the control group showed a clinical benefit of 3.8 (1.9) months. The difference in the duration of the clinical benefit between the 2 groups was 6.6 months (95% CI, 5.15-7.99). Adverse effects consisted of flushing, heat sensation during infusion, headache, and palpitations.Conclusions: In this study, histamine showed lasting prophylactic efficacy in migraineurs. If further research confirms this preliminary finding, histamine could be considered when established prophylactic drugs, such as betablockers, calcium antagonists, antidepressants, and antiepileptics, have not been effective. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
38. Mental pain as a global person-centered outcome measure.
- Author
-
Cosci F, Mansueto G, Benemei S, Chiarugi A, De Cesaris F, and Sensky T
- Subjects
- Humans, Cross-Sectional Studies, Pain psychology, Outcome Assessment, Health Care, Depression psychology, Quality of Life psychology, Migraine Disorders diagnosis
- Abstract
Background: Mental pain has been proposed as a global person-centered outcome measure. The aim of this cross-sectional study was to test an essential requisite of such a measure, namely that mental pain incorporates independent contributions from a range of discrete but disparate outcome measures., Methods: Two hundred migraine patients were assessed concerning migraine disability, psychosomatic syndromes, mental pain, depression, anxiety, and psychosocial dimensions. General linear models were tested to verify which measures would individually make unique contributions to overall mental pain., Results: The final model, accounting for 44% of variance, identified that higher mental pain was associated with more severe depressive symptoms, higher migraine disability, lower well-being, and poorer quality of life., Conclusion: In this sample, mental pain was shown to behave as expected of a global outcome measure, since multiple measures of symptomatology and quality of life showed modest but significant bivariate correlations with mental pain and some of these measures individually made unique contributions to overall mental pain.
- Published
- 2022
- Full Text
- View/download PDF
39. Mental pain and pain-proneness in patients with migraine: results from the PAINMIG cohort-study.
- Author
-
Cosci F, Svicher A, Mansueto G, Benemei S, Chiarugi A, De Cesaris F, Guidi J, and Zipfel S
- Subjects
- Adult, Disease Susceptibility, Female, Humans, Male, Middle Aged, Migraine Disorders psychology, Pain complications, Pain psychology, Personality, Migraine Disorders complications, Pain epidemiology
- Abstract
Background: Pain has been qualified under four categories: nociception, perception of pain, suffering, and pain behaviors. Most of the literature on migraine has devoted attention to the first two. The aim of the present cohort study was to investigate patients with migraine enrolled at a tertiary care unit to study suffering and mental pain and identify potential risk factors for migraine., Methods: An observational cross-sectional study was carried out on patients with chronic migraine (CM) and episodic migraine (EM), and healthy subjects (HS). The three groups were matched for age and sex. A comprehensive assessment of migraine disability, pain, psychiatric disorders, psychosomatic syndromes, depressive and anxious symptoms, euthymia, psychosocial variables, mental pain, and pain-proneness (PP) was performed., Results: Three hundred subjects were enrolled (100 CM, 100 EM, and 100 HS). Based on the multiple regression analyses, those presenting PP (social impairment: odds ratio [OR] = 3.59, 95% confidence interval [CI] = 1.14-11.29; depressive symptoms: OR = 3.82, 95% CI = 1.74-8.41) were more likely to be CM than HS. Those with higher levels of PP (social impairment: OR = 4.04, 95% CI = 1.60-10.22; depressive symptoms: OR = 2.02, 95% CI = 1.26-3.24) were more likely to be EM than HS. Those presenting higher levels of mental pain were more likely to be CM than EM (OR = 1.45, 95% CI = 1.02-2.07)., Conclusion: Migraine is an unpleasant sensory and emotional experience associated with psychosocial manifestations that might contribute to the level of suffering of the individuals. Mental pain resulted to be the variable that most differentiated patients with CM from EM.
- Published
- 2021
- Full Text
- View/download PDF
40. Criterion-related validity in a sample of migraine outpatients: the diagnostic criteria for psychosomatic research.
- Author
-
Cosci F, Svicher A, Romanazzo S, Maggini L, De Cesaris F, Benemei S, and Geppetti P
- Subjects
- Adult, Comorbidity, Depressive Disorder, Major epidemiology, Female, Humans, Male, Middle Aged, Migraine Disorders classification, Migraine Disorders epidemiology, Phobic Disorders epidemiology, Projective Techniques standards, Surveys and Questionnaires standards, Migraine Disorders diagnosis, Neuropsychological Tests standards
- Abstract
Objective: The Diagnostic Criteria for Psychosomatic Research (DCPR) are those of psychosomatic syndromes that did not find room in the classical taxonomy. More recently, the DCPR were updated, called DCPR-revised (DCPR-R). The present study was conducted to test the criterion-related validity of the DCPR-R., Methods: Two hundred consecutive subjects were enrolled at the Headache Center of Careggi University Hospital (Italy): 100 subjects had a diagnosis of chronic migraine (CM) and 100 had a diagnosis of episodic migraine (EM). Participants received a clinical assessment, which included the DCPR-revised Semi-Structured Interview (DCPR-R SSI), the Structured Clinical Interview for DSM-5 (SCID-5), and the psychosocial index (PSI)., Results: Forty-seven subjects (23.5%) had at least one DSM-5 diagnosis: major depressive disorder (8.5%; n = 17) and agoraphobia (7.5%; n = 15) were the most frequent. One hundred and ten subjects (55%) reported a DCPR-R diagnosis: allostatic overload (29%; n = 58) and type A behavior (10.5%; n = 21) were the most frequent. When the incremental validity of the DCPR system over the DSM system was tested using PSI subscales as the criterion variable, the DCPR-R increased up to 0.11-0.24 the amount of explained variance. Subjects with at least one DCPR-R diagnosis showed lower PSI well-being scores (p = .001), higher PSI stress scores (p < .001), and higher PSI psychological distress scores (p = .008) than subjects without a DCPR-R diagnosis., Conclusion: The DCPR-R showed a good criterion-related validity in migraine outpatients. Thus, they might be implemented, together with the DSM-5, in the assessment of migraine subjects.
- Published
- 2020
- Full Text
- View/download PDF
41. Transient receptor potential channels as novel drug targets in respiratory diseases.
- Author
-
Nassini R, Materazzi S, De Siena G, De Cesaris F, and Geppetti P
- Subjects
- Animals, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents therapeutic use, Humans, Neuropeptides metabolism, Respiratory System immunology, Respiratory System innervation, Respiratory System metabolism, Respiratory Tract Diseases immunology, Respiratory Tract Diseases metabolism, Sensory Receptor Cells drug effects, Sensory Receptor Cells immunology, Sensory Receptor Cells metabolism, Transient Receptor Potential Channels biosynthesis, Drug Design, Respiratory System drug effects, Respiratory Tract Diseases drug therapy, Transient Receptor Potential Channels antagonists & inhibitors
- Abstract
A subpopulation of nociceptive primary sensory neurons expresses six different transient receptor potential (TRP) ion channels of the vanilloid (V1, V2, V3 and V4), melastatin (M8) and ankyrin (A1) subtypes. TRPV1 mediates the tussive action of capsaicin, which is widely used in cough provocation studies. The upregulation of TRPV1 expression and function has been reported in asthma and other inflammatory conditions. TRPA1 is targeted by a series of byproducts of oxidative and nitrative stress, including acrolein, 4-hydroxy-2-nonenal and hydrogen peroxide. Proinflammatory neuropeptides are released from nociceptive nerve terminals after TRPV1/TRPA1 stimulation, thereby causing airway neurogenic inflammation. In addition, the early inflammatory response to cigarette smoke is mediated entirely by neuronal TRPA1. TRPV1 and TRPA1 antagonists may therefore represent potential antitussive and anti-inflammatory therapeutics for respiratory airway diseases.
- Published
- 2010
42. Migraine models.
- Author
-
Benemei S, De Cesaris F, Nicoletti P, Materazzi S, Nassini R, and Geppetti P
- Subjects
- Animals, Calcitonin Gene-Related Peptide metabolism, Cortical Spreading Depression physiology, Female, Humans, Male, Meninges blood supply, Migraine Disorders drug therapy, Radioimmunoassay instrumentation, Radioimmunoassay methods, Rats, Rats, Sprague-Dawley, Rats, Wistar, Receptors, Calcitonin Gene-Related Peptide metabolism, Regional Blood Flow, Disease Models, Animal, Migraine Disorders physiopathology
- Abstract
Migraine is a high prevalence disorder which affects a significant proportion of the general population, especially women during their central and more productive time of the life, thus causing severe disability. The genetic basis of the disease is unknown and the mechanism is poorly understood. The possibility that following a perturbation in the central nervous system, and particularly in the brainstem, trigeminal neurons become hyperexcitable and produce an uncontrolled release of sensory neuropeptides which eventually results in arterial vasodilatation and neuronal sensitization, has been gaining credit from studies in experimental animals and humans. In particular, experimental and clinical data with antagonists of the calcitonin gene-related peptide (CGRP) propose this molecule and its receptor as a major target for migraine treatment.
- Published
- 2010
- Full Text
- View/download PDF
43. Migraine.
- Author
-
Benemei S, Nicoletti P, Capone JG, De Cesaris F, and Geppetti P
- Subjects
- Afferent Pathways metabolism, Afferent Pathways physiopathology, Analgesics therapeutic use, Animals, Calcitonin Gene-Related Peptide Receptor Antagonists, Cerebrovascular Circulation, Efferent Pathways metabolism, Efferent Pathways physiopathology, Humans, Migraine Disorders complications, Migraine Disorders drug therapy, Migraine Disorders physiopathology, Neurogenic Inflammation metabolism, Neurogenic Inflammation physiopathology, Pain drug therapy, Pain metabolism, Pain physiopathology, Sensory Receptor Cells drug effects, Trigeminal Nerve drug effects, Trigeminal Nerve physiopathology, Vasodilation, Calcitonin Gene-Related Peptide metabolism, Migraine Disorders metabolism, Pain etiology, Receptors, Calcitonin Gene-Related Peptide metabolism, Sensory Receptor Cells metabolism, Trigeminal Nerve metabolism
- Abstract
Migraine is a neurovascular disorder which affects one fifth of the general population. Disability due to migraine is severe and involves patients from infancy through senescence and it is aggravated by the fact there is no complete cure. However, various drugs for the symptomatic or prophylactic treatment of the disease are available. Recently, better knowledge of the neurobiological and pharmacological aspects of a subset of trigeminal primary sensory neurons has provided key information for the development of effective molecules that specifically target the activation of the trigeminovascular system and may represent a significant advancement in the treatment of the disease. These novel antagonists block the receptor for the sensory neuropeptide calcitonin gene-related peptide (CGRP), which upon release from peripheral terminals of trigeminal perivascular neurons dilates cranial arterial vessels. Whether neurogenic vasodilatation is the major contributing factor to generate the pain and the associated symptoms of the migraine attack or whether other sites of action of CGRP receptor antagonists are responsible for the antimigraine effect of these compounds is the subject of current and intense research.
- Published
- 2009
- Full Text
- View/download PDF
44. Continuing follow-up of malignant hypertension.
- Author
-
Scarpelli PT, Gallo M, De Cesaris F, Chiari G, Dedola G, Cappeli S, Becucci A, Becherelli P, Tosi B, Fanetti C, and Fanelli R
- Subjects
- Adult, Age Distribution, Aged, Antihypertensive Agents therapeutic use, Blood Pressure Determination, Female, Follow-Up Studies, Humans, Hypertension, Malignant drug therapy, Male, Middle Aged, Risk Assessment, Severity of Illness Index, Sex Distribution, Survival Analysis, Hypertension, Malignant diagnosis, Hypertension, Malignant epidemiology, Monitoring, Physiologic methods, Nephrosclerosis prevention & control
- Abstract
The history of accelerated (malignant) hypertension is reviewed, and unsolved problems related to the disease are illustrated, including its relationship to malignant nephrosclerosis, as well as terminology, current frequency and treatment. Over the past 25 years, out of a series of 131 patients, 53 were classified as suffering from essential malignant hypertension, the only suitable model on which the effects of pharmacological treatment on the disease can correctly be evaluated. In 2000, there were 24 survivors in our series and the maximum follow-up was 290 months. Multiple daily B.P. self-measurements allowed us to establish that pharmacological treatment was only able to approximate, to a varying degree, the conventional threshold of 140/90. Yet, despite this incomplete control over blood pressure levels, renal function was maintained in those patients whose initial creatininemia levels had not been higher than 2 mg/L. The renal protection effect of treatment was preserved even in patients who relapsed intoaccelerated disease phase one or more times over the study period.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.